Biomea Fusion, Inc.
NASDAQ:BMEABiotechnology
-$0.03 today
- Market cap
- $53.18M
- Beta
- -0.33
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.62
Volume 3.50M
Average 1.52M
BMEA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Biomea Fusion, Inc.NASDAQ: BMEA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $9.12M fell 60.2% year over year, behind the -55.0% change in trailing-twelve-month research & development. Sequentially, it rose 12.4% from the prior quarter. Over 3 fiscal years it compounded at -0.4% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -60.2% toward the trailing-twelve-month pace of -55.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 61.98M USD
- Year-over-year change
- -47.5%
- 4-year CAGR
- +22.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 61.98M | -47.5% |
| FY2024 | 2024-12-31 | 118.09M | +15.2% |
| FY2023 | 2023-12-31 | 102.55M | +63.5% |
| FY2022 | 2022-12-31 | 62.71M | +124.0% |
| FY2021 | 2021-12-31 | 28M | — |
Research & Development vs competitors
How BMEA compares with its peers on the latest reported figures
- BMEA's LTM Mar 2026 research & development of $48.2M is the 6th highest of the 9 companies compared; the peer median is $67.21M.
- Its year-over-year change of -55.0% is the lowest of 9, against a peer median of -12.2%.
- Over three fiscal years its annual growth of -0.4% compares with a peer median of +6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.37M | -38.7% | +6.7% | 152.0% | |
| LTM Mar 2026 | $86.08M | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $70.7M | -6.3% | +29.5% | — | |
| LTM Mar 2026 | $67.7M | +8.5% | +10.6% | — | |
| LTM Mar 2026 | $66.71M | -38.5% | -7.9% | — | |
| LTM Mar 2026 | $48.2M | -55.0% | -0.4% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $41.12M | -18.1% | +56.4% | 959.3% |
| LTM Mar 2026 | $37.7M | -3.9% | — | 958.2% | |
| LTM Mar 2026 | $8.57M | -44.2% | -9.8% | — | |
| Peer median (excluding BMEA) | $67.21M | -12.2% | +6.7% | 958.2% | |
Competitors are the stored peer set for BMEA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.41M |
| Gross Profit | 0 | 0 | 0 | 0 | (1.41M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 28M | 62.71M | 102.55M | 118.09M | 61.98M |
| Selling, General & Admin | 13.67M | 20.92M | 23.59M | 25.99M | 19.33M |
| Operating Expenses | 41.67M | 83.63M | 126.14M | 144.07M | 79.9M |
| Depreciation & Amortization | 249K | 691K | 1.52M | 1.75M | 1.41M |
| EBITDA | (41.32M) | (81.14M) | (115.74M) | (136.68M) | (60.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (41.67M) | (83.63M) | (126.14M) | (144.07M) | (81.31M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 100K | 1.81M | 8.88M | 5.64M | 1.86M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 100K | 1.81M | 8.88M | 5.64M | 19.51M |
| Income Before Tax | (41.57M) | (81.83M) | (117.26M) | (138.43M) | (61.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (41.57M) | (81.83M) | (117.26M) | (138.43M) | (61.8M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.74) | (2.80) | (3.44) | (3.83) | (1.18) |
| EPS (Diluted) | (1.74) | (2.80) | (3.44) | (3.83) | (1.18) |
| Weighted Avg Shares | 23.86M | 29.27M | 34.11M | 36.11M | 52.23M |
| Weighted Avg Shares (Diluted) | 23.86M | 29.27M | 34.11M | 36.11M | 52.23M |
Biomea Fusion, Inc.
NASDAQ:BMEA
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.